Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA‐B*5701 Screening as a Risk‐Mitigation Measure

INTRODUCTION: Human leukocyte antigen (HLA)‐B*5701 screening identifies patients at increased risk for abacavir (ABC) hypersensitivity reaction (HSR). Screening was adopted in GlaxoSmithKline and ViiV Healthcare clinical trials in 2007 and human immunodeficiency virus treatment guidelines in 2008. C...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Pharmacotherapy
Auteurs principaux: Stainsby, Chris M., Perger, Teodora M., Vannappagari, Vani, Mounzer, Karam C., Hsu, Ricky K., Henegar, Cassidy E., Oyee, James, Urbaityte, Rimgaile, Lane, Charlotte E., Carter, Lindsay M., Pakes, Gary E., Shaefer, Mark S.
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2018
Sujets:
Original Research Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6590466/
https://ncbi.nlm.nih.gov/pubmed/30414209
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/phar.2196
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires